Clinical trials: Prostate Cancer Patients Treated by Radiotherapy
Prostate Cancer
Prostate Cancer Survey
There have been calls from patients, payers, healthcare providers, and policy makers for an evaluation of newer, high-cost radiation technologies compared to conventional forms of radiation therapy.
- Trial name
- NCT03128710
- Where
- United States
- Volunteers
- 224 people
- Sponsor
- University of Maryland, Baltimore
Metastatic Cancer, Pain
Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain
RATIONALE: Ibandronate may be effective in reducing bone pain caused by metastatic cancer. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Metastatic Cancer, Pain, Prostate Cancer
- Trial name
- NCT00082927
- Testing
- ibandronate sodium
- Where
- 52 sites in United Kingdom
- Volunteers
- 580 people
- Sponsor
- Cancer Research UK
Prostate Cancer Patients Treated by Radiotherapy
Efficacy and Safety of Simultaneous Integrated Boost Radiotherapy in HR/VHR Prostate Cancer With EPLNI
The aim of this study is to evaluate the efficacy and safety of hypofractionated simultaneous integrated boost volumetric arc radiation therapy (SIB - VMAT) for high-risk and very high-risk localized prostate cancer in terms of…
- Trial name
- SIB-VMAT (NCT07693075)
- Testing
- Simultaneous Integrated Boost Volumetric Modulated Arc Therapy (SIB-VMAT)
- Where
- 3 sites in Egypt
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Adenocarcinoma of the Prostate, Stage I Prostate Cancer
Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy, such as intensity-modulated radiation therapy, that delivers a high dose of radiation directly…
- Conditions
- Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT01117935
- Testing
- intensity modulated external beam radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Virginia Commonwealth University
Prostate Cancer
Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00619515
- Testing
- questionnaire administration, implanted fiducial-based imaging, stereotactic radiosurgery
- Where
- 4 sites in United States
- Volunteers
- 73 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using triptorelin and flutamide may fight cancer by reducing the production of androgens.
- Trial name
- NCT00003734
- Testing
- flutamide, triptorelin, radiation therapy
- Where
- 12 sites in Ireland, United Kingdom
- Volunteers
- 276 people
- Sponsor
- St. Luke's Hospital, Ireland
Prostate Cancer
Adjuvant Treatment of Prostate Cancer With Docetaxel or Not After Radical Radiotherapy
As docetaxel is proven to be effective in late stages of prostate cancer with a large tumour burden it should be effective in primarily treated intermediate and high risk prostate cancer as an adjuvant treatment after…
- Trial name
- AdRad (NCT00653848)
- Testing
- docetaxel
- Where
- Norway
- Volunteers
- 378 people
- Sponsor
- Scandinavian Prostate Cancer Group
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of conventional radiation therapy with high-dose radiation therapy in treating men with…
- Trial name
- NCT00002703
- Testing
- high-LET heavy ion therapy, low-LET photon therapy
- Where
- 2 sites in United States
- Volunteers
- 390 people
- Sponsor
- Proton Radiation Oncology Group
Adenocarcinoma of the Prostate
Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate
The purpose of this study is to determine the feasibility and late toxicity of dose escalated radiation therapy to the pelvic lymph nodes and prostate and seminal vesicles in the treatment of high risk prostate cancer.
- Trial name
- NCT00915122
- Testing
- Dose Escalated IMRT
- Where
- Canada
- Volunteers
- 81 people
- Sponsor
- University Health Network, Toronto
Cancer
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses x-rays to damage tumor cells.
- Trial name
- NCT00003704
- Testing
- capecitabine, radiation therapy
- Where
- 18 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Prostate Cancer - Patient Empowerment Program
Each year over 20,000 men are diagnosed with prostate cancer in Canada with the majority undergoing some form of treatment option.
- Trial name
- PC-PEP (NCT03660085)
- Testing
- PC-PEP
- Where
- Canada
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Nova Scotia Health Authority
Prostate Cancer Patients Treated by Radiotherapy
A Reminder App to Optimize Bladder Filling in Patients with Prostate Cancer Receiving HYPO-fractionated Radiotherapy
The primary goal of this study is to assess the impact of an app that reminds patients treated with hypofractionated radiotherapy (HF-RT) for prostate cancer to drink water prior to each radiotherapy session on the number of…
- Trial name
- REFILLPAC-HYPO (NCT06784115)
- Testing
- Reminder App
- Where
- 4 sites in Denmark, Germany and 1 more
- Volunteers
- 27 people
- Sponsor
- University Hospital Schleswig-Holstein
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00258466
- Testing
- radiation therapy
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
This phase Ib trial tests the safety, side effects, and best dose of autologous anti-prostate stem cell antigen (PSCA)-chimeric antigen receptor (CAR)-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (PSCA-CAR T cells), plus or minus…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT05805371
- Testing
- Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Biopsy, Biospecimen Collection
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, Glioma
A Study of Gene Polymorphisms and Normal Tissue Radiation Injury in Patients Treated for Breast, Prostate, Brain, Lung, and Head and Neck Cancers
This study will examine, for the first time, the independent contribution of a patient's own genetic makeup to the development of post-radiation complications, permitting the future development of predictive tests to avoid…
- Conditions
- Breast Cancer, Glioma, Prostate Cancer, Carcinoma, Squamous Cell
- Trial name
- NCT00122239
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- AHS Cancer Control Alberta
Prostate Cancer
Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer
RATIONALE: Giving samarium Sm 153 lexidronam pentasodium and 3-dimensional (3-D) conformal radiation therapy or intensity-modulated radiation therapy may keep prostate cancer from growing in patients with rising prostate-specific…
- Trial name
- NCT00551525
- Testing
- Radiotherapy, Samarium 153
- Where
- 29 sites in United States
- Volunteers
- 67 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer (Diagnosis), Prostate Cancer Patients Who Have Brachytherapy Seed Implant
Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy
Analysis of peripheral immune cells before, during, and after brachytherapy treatment. Corresponding analysis of tissue samples collected during brachytherapy treatment.
- Conditions
- Prostate Cancer (Diagnosis), Prostate Cancer Patients Who Have Brachytherapy Seed Implant, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer Recurrent
- Trial name
- NCT07131956
- Where
- 3 sites in Germany
- Volunteers
- 200 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Prostate Cancer
Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients
The study aims to identify potential urine marker metabolites as predictive or prognostic markers for treatment outcomes in patients with prostate cancer.
- Trial name
- NCT03237026
- Testing
- No intervention required
- Where
- Taiwan
- Volunteers
- 360 people
- Sponsor
- National Taiwan University Hospital
Prostate Cancer
Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00002597
- Testing
- flutamide, Zoladex, Lupron
- Where
- 239 sites in United States, Canada
- Volunteers
- 2,028 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Radiation Therapy With or Without Goserelin and Cyproterone in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high energy x rays to kill tumor cells. This may be an effective treatment for prostate cancer. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00849082
- Testing
- cyproterone acetate, goserelin acetate, radiation therapy
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC